within Pharmacolibrary.Drugs.M_MusculoSkeletalSystem.M02A_TopicalProductsForJointAndMuscularPain.M02AA07_Piroxicam;

model Piroxicam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.9,
    Cl = 3.111111111111111e-08,
    adminDuration = 600,
    adminMass = 20 / 1000000,
    adminCount = 1,
    Vd = 0.0158,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0009666666666666667,
    Tlag = 30.0,
    Vdp = 0.0096,
    k12 = 1.8888888888888894e-08,
    k21 = 1.8888888888888894e-08);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Piroxicam</td></tr><tr><td>ATC code:</td><td>M02AA07</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>20</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>15.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.112</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class, used to relieve the symptoms of painful, inflammatory conditions like osteoarthritis and rheumatoid arthritis. It is an approved drug in many countries and is usually administered orally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after a single oral dose.</p><h4>References</h4><ol><li><p>Palma-Aguirre, JA, et al., &amp; González-de la Parra, M (2010). Relative bioavailability of two oral formulations of piroxicam 20 mg: a single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Mexican adult volunteers. <i>Clinical therapeutics</i> 32(2) 357–364. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2010.02.002\">10.1016/j.clinthera.2010.02.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20206793/\">https://pubmed.ncbi.nlm.nih.gov/20206793</a></p></li><li><p>Calvo, AM, et al., &amp; Santos, CF (2016). Effective method for the detection of piroxicam in human plasma using HPLC. <i>Brazilian oral research</i> 30(1) –. DOI:<a href=\"https://doi.org/10.1590/1807-3107BOR-2016.vol30.0058\">10.1590/1807-3107BOR-2016.vol30.0058</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27223141/\">https://pubmed.ncbi.nlm.nih.gov/27223141</a></p></li><li><p>Mailhot, C, et al., &amp; Ward, JR (1986). The effect of cimetidine on serum concentrations of piroxicam. <i>Pharmacotherapy</i> 6(3) 112–117. DOI:<a href=\"https://doi.org/10.1002/j.1875-9114.1986.tb03464.x\">10.1002/j.1875-9114.1986.tb03464.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3488542/\">https://pubmed.ncbi.nlm.nih.gov/3488542</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.M.M02AA07 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Piroxicam;
